Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3819026 and Ezabenlimab in Advanced Solid Cancers
NCT07607678Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of BI 3819026 in solid tumor cancer (8 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Dose-Limiting Toxicities at 30 days. Started May 2026; status: recruiting.
02
Drugs
BI 3819026
03
Conditions
solid tumor cancer
Beyond the preview
Go deeper on NCT07607678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607678.